AHC is a dubious disease in the field of genetic metabolism, with clinical performance being complex and often involving multiple systems. Early identification and standardization clinically are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of AHCs require multi-disciplinary development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and so on. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat genetic metabolic disorders have been significantly improved.
Treatment requires close monitoring of therapeutic effects and adverse reactions, adapting to timely schemes depending on the changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of AHC. The platform serves a team of domestic and foreign experts in the field of genetic metabolism in China, providing the following services to patients: 1.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.